2023 ESMO：一文速览5大癌种重点研究题目

2023年欧洲肿瘤内科学会（ESMO）年会将于当地时间10月20日至24日在西班牙马德里召开。作为全球最具影响力的肿瘤学会议之一，ESMO官方近日披露了除LBA之外的其他摘要题目，小编整理了肺癌、乳腺癌、消化系统肿瘤、中枢神经系统肿瘤、妇科肿瘤药物治疗重点研究，以飨读者。

肺癌

摘要号：1312MO

标题：Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II)

结合抗原呈递细胞激活剂eftilagimod alpha（可溶性LAG-3）和pembrolizumab：来自TACTI-002（II期）研究一线治疗NSCLC队列的OS数据

摘要号：1261O

标题：Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase 3 CheckMate 816 trial

Ⅲ期CheckMate 816：新辅助纳武利尤单抗（N）+伊匹木单抗（I） vs 化疗（C）

摘要号：1314MO

标题：TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

TROPION-Lung05：datopotamab deruxtecan（Dato-DXd）治疗既往经治的具有可靶向基因组改变（AGA）的NSCLC

摘要号：1315MO

标题：Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

HER2×HER3双特异性抗体zenocutuzumab在晚期NRG1融合阳性（NRG1+）非小细胞肺癌 ( NSCLC )中的持久疗效

摘要号：1321MO

标题：Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2 (ERBB2)-Mutant (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC) With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-Lung01 and DESTINY-Lung02

DESTINY-Lung01和DESTINY-Lung02汇总分析：德曲妥珠单抗（T-DXd）治疗HER2（ERBB2）突变（HER2m）伴/不伴脑转移（BM）的转移性NSCLC

摘要号：1319MO

标题：Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01

HERTHENA-Lung01：HER3-DXd治疗既往经治的晚期EGFR突变NSCLC的颅内活性

摘要号：1320MO

标题：Phase II trial of amivantamab plus lazertinib in patients with EGFR-mutant lung cancers with leptomeningeal metastases

埃万妥单抗联合拉泽替尼治疗伴有软脑膜转移的EGFR突变肺癌患者的II期试验

摘要号：1317MO

标题：Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC) pelcitoclax（APG-1252）联合奥希替尼治疗EGFR突变型非小细胞肺癌（NSCLC）患者(pts)的最新研究结果

乳腺癌

摘要号：240MO

标题：Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)

monarchE研究的探索性分析：ER/PR和Ki-67表达对高风险、HR阳性、HER2阴性早期乳腺癌患者预后和预测的影响

摘要号：376O

标题：Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study

随机、Ⅲ期DESTINY-Breast04研究更新的生存结果：德曲妥珠单抗 vs 医生选择的治疗 (TPC) 治疗HER2低表达不可切除和/或转移性乳腺癌患者

摘要号：377O

标题：A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

DESTINY-Breast (DB) -01、DB-02和DB-03研究的汇总分析：德曲妥珠单抗治疗伴脑转移的HER2阳性转移性乳腺癌患者

摘要号：379MO

标题：Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

Ⅰb/Ⅱ期BEGONIA研究的更新结果：Dato-DXd+度伐利尤单抗一线治疗不可切除局部晚期/转移性三阴性乳腺癌患者

摘要号：386MO

标题：Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial

trastuzumab duocarmazine与医生选择的疗法治疗既往治疗过的 HER2 阳性转移性乳腺癌：III 期 TULIP 试验的最终结果

摘要号：384MO

标题：Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)

氟维司群与阿那曲唑在未经内分泌治疗 (ET) 的激素受体阳性 (HR+) 晚期乳腺癌 (FALCON) 中的最终总体生存分析

消化系统肿瘤

胃食管癌

摘要号：1511O

标题：Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled KEYNOTE-811 Study

Ⅲ期、随机、双盲、安慰剂对照KEYNOTE-811研究的生存结果：帕博利珠单抗+曲妥珠单抗+化疗治疗HER2+转移性胃或食管胃交界部（mG/GEJ）腺癌 

摘要号：1512MO

标题：Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase 3 trial (DRAGON IV)

随机、Ⅲ期试验（DRAGON IV）的首次期中分析：围术期卡瑞利珠单抗（C）+ rivoceranib（R）+化疗（chemo） vs. chemo治疗局部晚期可切除胃或食管胃交界部（G/GEJ）腺癌

胰腺癌

摘要号：1616O

标题：Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase 2/3 trial

多中心、随机、开放、三臂、Ⅱ/Ⅲ期研究（JCOG1611, GENERATE）：白蛋白结合型紫杉醇+吉西他滨 vs. mFOLFIRINOX或S-IROX治疗转移性或复发性胰腺癌

肝癌

摘要号：945MO 标题：AdvanTIG-206: Phase 2 Randomized Open-Label Study of Ociperlimab (OCI) + Tislelizumab (TIS) + BAT1706 (Bevacizumab Biosimilar) Versus TIS + BAT1706 in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC) AdvanTIG-206：Ociperlimab（OCI）+替雷利珠单抗（TIS）+BAT1706（贝伐珠单抗生物类似物）vs TIS + BAT1706治疗晚期肝细胞癌（HCC）患者（pts） 的Ⅱ期随机开放标签研究

胆管癌

摘要号：94MO

标题：Advanced extrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials

晚期肝外胆管癌：ABC-01、-02和-03临床试验的事后分析

摘要号：95MO

标题：Tinengotinib in Patients with Advanced, Fibroblast Growth Factor Receptor (FGFR) inhibitor Refractory/Relapsed Cholangiocarcinoma

tinengotinib用于治疗晚期成纤维细胞生长因子受体 (FGFR) 抑制剂难治性/复发性胆管癌患者

结直肠癌

摘要号：550O 标题：Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): a phase II study D-1553联合西妥昔单抗治疗KRAS G12C突变结直肠癌（CRC）安全性和有效性的II期研究

摘要号：554MO 标题：Cetuximab Plus FOLFOXIRI Versus Cetuximab Plus FOLFOX as conversion therapy in RAS Wild-type Patients with Initially Unresectable Colorectal Liver 西妥昔单抗加FOLFOXIRI vs.西妥昔单抗加FOLFOX作为RAS野生型初始不可切除结直肠肝患者的转化疗法

摘要号：556MO 标题：A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer 信迪利单抗加西达本胺联合或不联合贝伐珠单抗治疗MSS/pMMR转移性结直肠癌患者的II期临床试验

摘要号：559MO

标题：Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: individual patients’ data pooled analysis from 4 phase II trials.

四项Ⅱ期研究的个体患者数据汇总分析：在 ctDNA RAS/BRAF 野生型难治性转移性结直肠癌中使用 EGFR 抑制剂进行再挑战

中枢神经系统肿瘤

摘要号：500O

标题：Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): updated results from a phase 1b/2 study

Ib/II期研究的最新结果：Trotabresib（CC-90010）+替莫唑胺（TMZ）+放疗（RT）和辅助TMZ治疗新诊断的原发性胶质母细胞瘤（ndGBM）患者

摘要号：499O

标题：A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated

一项II期研究：旨在探索 FCN-159 在 MAPK 通路激活的复发性或进行性儿童低级别胶质瘤 (pLGG) 中的有效性和安全性

摘要号：498O

标题：INDIGO: a randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma

随机、双盲、Ⅲ期INDIGO试验：Vorasidenib vs 安慰剂治疗IDH1/IDH2低级别胶质瘤

摘要号：501O

标题：Glasdegib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib/II GEINO 1602 trial

Ⅰb/Ⅱ期GEINO 1602试验：Glasdegib+替莫唑胺+放疗治疗新诊断的胶质母细胞瘤

妇科肿瘤

卵巢癌

摘要号：746MO

标题：Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)

在既往接受贝伐珠单抗治疗的铂耐药卵巢癌患者中，比较度伐利尤单抗+奥拉帕利+西地尼布（DOC） vs. 奥拉帕利+西地尼布（OC）或度伐利尤单抗+西地尼布（DC）或标准化疗（SOC）的随机Ⅱ期试验（NRG-GY023）

摘要号：747MO

标题：First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)

ENGOT-GYN2/GOG-3051/BOUQUET Ⅱ期生物标志物导向平台研究的首次结果：cobimetinib（cobi）或阿替利珠单抗（atezo）+贝伐珠单抗（bev）治疗持续性/复发性罕见上皮性卵巢癌（eOC）

宫颈癌

摘要号：743MO

标题：Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase II study

QL1706 +紫杉醇+顺铂/卡铂±贝伐珠单抗（Bev）作为复发或转移性宫颈癌（r/mCC）1L治疗的疗效和安全性：一项单臂、多中心Ⅱ期研究

摘要号：744MO

标题：AdvanTIG-202: Phase 2 Randomized, Multicenter, Open-Label Study of Tislelizumab (TIS) With or Without Ociperlimab (OCI) in Patients (pts) With Previously Treated Recurrent/Metastatic (R/M) Cervical Cancer (CC)

AdvanTIG-202：替雷利珠单抗（TIS）± ociperlimab（OCI）治疗既往经治的复发/转移性（R/M）宫颈癌（CC）的Ⅱ期随机、多中心、开放研究

子宫内膜癌

摘要号：740MO

标题：Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

多塔利单抗+化疗治疗原发性晚期或复发性子宫内膜癌（pA/rEC）：ENGOT-EN6-NSGO/GOG-3031/RUBY试验中根据分子分型分析的无进展生存期（PFS）和总生存期（OS）结果

声明：本资料中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。

本文版权归找药宝典所有，任何个人或机构转载需获得找药宝典授权，在授权范围内使用，并标注来源“找药宝典”。

打赏